Clinical Trial Update: Study for Patients Who Have Benefited and Tolerated Prior Panitumumab Treatment [Phase 2]

View source ↗

Summary

Phase 2 study evaluating continuation of panitumumab in patients who previously benefited and tolerated the drug has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer
• Non-small Cell Lung Cancer
• Prostate Cancer
• Renal Cell Carcinoma
• Solid Tumors

Drugs mentioned

• Panitumumab (panitumumab)

Snippet

Sponsor: Amgen | Conditions: Colorectal Cancer, Non-Small Cell Lung Cancer | Phase 2 | Status: COMPLETED